8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Mar 5, 2026·SEC
Nutex Health, Inc.(NUTX)Earnings, Financials & Key Ratios
NUTX•NASDAQ
$193.54
18.5× P/E·Price updated Jul 6, 2026
AboutNutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.Show more
- Revenue$875M+82.4%
- EBITDA$296M+98.0%
- Net Income$71M+35.7%
- EPS (Diluted)10.48+7.9%
- Gross Margin50.76%+24.1%
- EBITDA Margin33.84%+8.6%
- Operating Margin31.49%+15.7%
- Net Margin8.09%-25.6%
- ROE22.64%-39.0%
NUTX Price & Volume
Nutex Health, Inc. (NUTX) stock price & volume — 10-year historical chart
Loading chart...
Volatile Operational Scaling Masks Significant Financial Deleveraging
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Regulatory reimbursement volatility
Key Thesis Takeaways
- Nutex Health exhibits a complex financial profile characterized by extreme revenue volatility, evidenced by a 41.1% contraction in 2025Q4, and significant earnings distortion from stock-based compensation reaching $106.4 million in 2025Q2.
- While the company has successfully improved its liquidity position and reduced its debt-to-equity ratio to 0.60 as of 2026Q1, the underlying business model remains highly sensitive to regulatory reimbursement shifts and high fixed-cost clinical requirements.
- Investors should exercise caution as the firm attempts to stabilize its decentralized micro-hospital footprint while navigating erratic cash conversion cycles.
Verdict Logic
while the current P/E of 15.88 and improved liquidity with $207.3 million in cash are notable, the extreme volatility in quarterly earnings and historical reliance on equity-based financing warrant a wait-and-see approach.
NUTX Growth Metrics
Nutex Health, Inc. (NUTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years26.14%
3 Years58.62%
TTM40.95%
Profit CAGR
10 Years96.19%
5 Years-7.75%
3 Years-
TTM43.47%
EPS CAGR
10 Years74.25%
5 Years-15.75%
3 Years-
TTM8.36%
Return on Capital
10 Years-32.65%
5 Years1.57%
3 Years21.65%
Last Year43.23%
NUTX Recent Earnings
Nutex Health, Inc. (NUTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (50%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$6.52+63.4%
$3.99
Rev
$216M-5.0%
$228M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$1.61-71.0%
$5.56
Rev
$152M-41.4%
$259M
Q4 2025
Nov 19, 2025Metric
Actual
Est
EPS
$7.76+328.7%
$1.81
Rev
$268M+25.3%
$214M
Q4 2025
Oct 22, 2025Metric
Actual
Est
EPS
$2.95-105.8%
$1.43
Rev
$244M-0.0%
$244M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $6.52vs $3.99+63.4% | $216Mvs $228M-5.0% |
| Q2 2026 | Mar 5, 2026 | $1.61vs $5.56-71.0% | $152Mvs $259M-41.4% |
| Q4 2025 | Nov 19, 2025 | $7.76vs $1.81+328.7% | $268Mvs $214M+25.3% |
| Q4 2025 | Oct 22, 2025 | $2.95vs $1.43-105.8% | $244Mvs $244M-0.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Nutex Health, Inc. (NUTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $193.54 | $1.15B | 18.47 | 82.36% | 8.09% | 22.64% | — | |
| $105.73 | $1.97B | 20.29 | 23.21% | 6.89% | 9.34% | — | |
| $34.65 | $651.24M | 14.03 | 2.63% | 14.27% | 9.68% | — | |
| $158.05 | $9.89B | 6.84 | 9.71% | 8.56% | 20.65% | — | |
| $191.20 | $16.75B | 12.34 | 3.12% | 7.94% | 19.56% | — | |
| $3.68 | $518.63M | 0.98 | -1.18% | -0.41% | — | — |
Compare NUTX vs Peers
Nutex Health, Inc. (NUTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NUTX SEC Filings & Documents
Nutex Health, Inc. (NUTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NUTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NUTX Frequently Asked Questions
Nutex Health, Inc. (NUTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Nutex Health, Inc.'s revenue?
Nutex Health, Inc. (NUTX) reported $880.0M in revenue for fiscal year 2025. This represents a 69387% increase from $1.3M in 2010.
How fast is Nutex Health, Inc. growing?
Nutex Health, Inc. (NUTX) grew revenue by 82.4% over the past year. This is strong growth.
Is NUTX profitable?
Yes, Nutex Health, Inc. (NUTX) is profitable, generating $96.4M in net income for fiscal year 2025 (8.1% net margin).
Dividend & Returns
What is NUTX's return on equity?
Nutex Health, Inc. (NUTX) has a return on equity (ROE) of 22.6%. This is excellent, indicating efficient use of shareholder capital.
What is Nutex Health, Inc.'s free cash flow?
Nutex Health, Inc. (NUTX) generated $270.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.